報價延遲最少15分鐘:2026/01/11 12:53 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.28 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.54/1.27
|
|
企業價值
381.52M
|
| 資產負債 |
|
每股賬面淨值
1.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer'sdisease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and severalother compounds in different stages of clinical and pre-clinical development. |
